• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Otitis Media - Pipeline Review, H1 2012 Product Image

Otitis Media - Pipeline Review, H1 2012

  • ID: 2075554
  • February 2012
  • 45 pages
  • Global Markets Direct

Otitis Media – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Otitis Media - Pipeline Review, H1 2012', provides an overview of the Otitis Media therapeutic pipeline. This report provides information on the therapeutic development for Otitis Media, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Otitis Media. 'Otitis Media - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Otitis Media.
- A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Otitis Media Overview
Therapeutics Development
An Overview of Pipeline Products for Otitis Media
Otitis Media Therapeutics under Development by Companies
Otitis Media Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Otitis Media Therapeutics – Products under Development by Companies
Otitis Media Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Otitis Media Therapeutics Development
OctoPlus N.V.
Mucosis B.V.
Otonomy, Inc.
Laboratorios SALVAT S.A.
Otitis Media – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DPK-060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OP-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OTO-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PneuGEM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xylitol Syrup - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PNCRM9 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Juzen-Taiho-To - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetraxal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Ear Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meiact MS Fine Granules - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Otitis Media Therapeutics – Drug Profile Updates
Otitis Media Therapeutics - Dormant Products
Otitis Media – Product Development Milestones
Featured News & Press Releases
Jan 16, 2012: Pergamum Initiates Phase II Trial With DPK-060 In Outer Ear Infections
Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201
Jan 08, 2010: LG Life Sciences Receives Approval For Additional Indication Of Factive For Otitis Media
Jul 28, 2009: Wyeth recalls lot of Prevnar vaccine.
Jul 28, 2008: OctoPlus Proves Efficacy Of OP-145 In Phase II Ear Infection Study
Oct 04, 2007: Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease.
Jul 27, 2007: Wyeth Team Recognized by White House With Prestigious National Medal of Technology for PREVNAR Vaccine.
Nov 22, 2006: OctoPlus Grants Green Cross Corporation Exclusive Korean License To OP-145
Jul 05, 2006: Octoplus Obtains Full Rights To OP-145 For The Treatment Of Chronic Middle Ear Infection And Other Indications
Mar 07, 2006: Octoplus Initiates Phase II Clinical Trials With OP-145 In Chronic Middle Ear Infection And Presents Positive Phase I Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Otitis Media, H1 2012
Products under Development for Otitis Media – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
OctoPlus N.V., H1 2012
Mucosis B.V., H1 2012
Otonomy, Inc., H1 2012
Laboratorios SALVAT S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Otitis Media Therapeutics – Drug Profile Updates
Otitis Media Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Otitis Media, H1 2012
Products under Development for Otitis Media – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos